Alvotech (ALVO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alvotech (ALVO) has a cash flow conversion efficiency ratio of 0.314x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Ikr-55.58 Million ≈ $-453.08K USD) by net assets (Ikr-176.76 Million ≈ $-1.44 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Alvotech to measure how many days the company can operate on defensive assets alone.
Alvotech - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Alvotech's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alvotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alvotech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SKAN Group AG
SW:SKAN
|
0.312x |
|
SUPERLOOP LTD
F:9SL
|
N/A |
|
Chengdu Guibao Science Tech
SHE:300019
|
0.077x |
|
Puuilo Oyj
HE:PUUILO
|
0.214x |
|
Siam Global House Public Company Limited
BK:GLOBAL
|
0.245x |
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
0.165x |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
0.044x |
|
HBM HLDGS LTD DL-000025
F:6XY
|
N/A |
Annual Cash Flow Conversion Efficiency for Alvotech (2020–2024)
The table below shows the annual cash flow conversion efficiency of Alvotech from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see Alvotech (ALVO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Ikr-412.77 Million ≈ $-3.37 Million |
Ikr-236.84 Million ≈ $-1.93 Million |
0.574x | +71.39% |
| 2023-12-31 | Ikr-932.49 Million ≈ $-7.60 Million |
Ikr-312.19 Million ≈ $-2.55 Million |
0.335x | -39.51% |
| 2022-12-31 | Ikr-564.42 Million ≈ $-4.60 Million |
Ikr-312.39 Million ≈ $-2.55 Million |
0.553x | -67.10% |
| 2021-12-31 | Ikr-135.61 Million ≈ $-1.11 Million |
Ikr-228.17 Million ≈ $-1.86 Million |
1.683x | +1864.00% |
| 2020-12-31 | Ikr-867.24 Million ≈ $-7.07 Million |
Ikr-74.30 Million ≈ $-605.70K |
0.086x | -- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more